Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Armstrong, A. J.; Tombal, B.; Sternberg, C. N.; Higano, C. S.; Rathkopf, D. E.; Loriot, Y.; Saad, F.; Joshua, A. M.; de Bono, J. S.; Venner, P. M.; Caries, J.; Mainwaring, P. N.; Evans, C. P.; Noonberg, S. B.; Mansbach, H. H.; Bhattacharya, S.; Perabo, F.; De, Phung; Beer, T. M. |
| Abstract Title: | Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613203401 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.5007 |
| Notes: | Meeting Abstract: 5007 -- 50th Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 30-JUN 03, 2014 -- Chicago, IL -- S -- Source: Wos |
